Thornton Law Firm Announces Investigation into Revance Therapuetics
Back to Newsroom
Mentioned in this Article

Thornton Law Firm Announces Investigation into Revance Therapuetics

Monday, October 18, 2021 12:00 PM
Share this article now
Topic:
Lawsuits
Thornton Law Firm LLP

BOSTON, MA / ACCESSWIRE / October 18, 2021 / The Thornton Law Firm alerts investors that it is investigating Revance Therapeutics, Inc. (NASDAQ:RVNC) for potential securities violations. Investors who currently own shares or options of RVNC may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Revance for more information. Investors may also email [email protected] or call 617-531-3917.

Thornton Law Firm LLC, Attorneys At Law logo

FOR MORE INFORMATION: www.tenlaw.com/cases/Revance

On October 15, 2021, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Revance Therapeutics, Inc., citing deficiencies found during an inspection at the Company's manufacturing facility for its wrinkle injection treatment, DaxibotulinumtoxinA, or DAXI (a competing product to BOTOX). Previously, shares of Revance Therapeutics fell over 25% in intraday trading on October 12, 2021 after Form 483 was posted to the FDA's website. Shares fell over 30% in after hours trading on October 15, 2021 following news of the FDA letter.

FOR MORE INFORMATION: www.tenlaw.com/cases/Revance

Thornton Law Firm's securities attorneys are highly experienced in representing investors in recovering damages caused by violations of the securities laws. Its attorneys have established track records litigating securities cases in courts throughout the country and recovering losses on behalf of investors. This may be considered Attorney Advertising in some jurisdictions. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

CONTACT:
Thornton Law Firm LLP
1 Lincoln Street
State Street Financial Center
Boston, MA 02111

www.tenlaw.com/cases/Revance

SOURCE: Thornton Law Firm LLP

Back to Newsroom
Copyright 2022 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions